Get the Stockscreener App
320.86
0.11%
-0.34
Penumbra Inc stock is traded at $320.86, with a volume of 278.51K.
It is down -0.11% in the last 24 hours and up +0.77% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$321.20
Open:
$322.8
24h Volume:
278.51K
Relative Volume:
0.83
Market Cap:
$12.64B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
73.83
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
+0.46%
1M Performance:
+0.77%
6M Performance:
-3.20%
1Y Performance:
+26.40%
1-Day Range:
$320.15
$322.80
1-Week Range:
$318.26
$322.80
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
320.86 | 12.64B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
MarketBeat cites USD 367.07 average target for Penumbra stock - ad-hoc-news.de
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story? - Kalkine Media
Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus - Yahoo Finance
Penumbra presented STORM-PE data while Penumbra stock trades at EUR 281.30 - AD HOC NEWS
Penumbra (BSP:P2NB34) Total Tax Payable : R$ Mil (As of Jun. 2026) - GuruFocus
Operating cash flow per share of Penumbra, Inc. – HAN:0P8 - TradingView
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - BioSpace
Penumbra stock gets fresh STORM-PE data catalyst - AD HOC NEWS
Behavioral Patterns of PEN and Institutional Flows - Stock Traders Daily
Penumbra (PEN) Highlights Wearable Device Data Linking Activity to Recovery in Pulmonary Embolism Trial - GuruFocus
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - PR Newswire
In a lung-clot study, fitness-watch steps lined up with clinic walking tests - Stock Titan
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - Nasdaq
Penumbra stock reports 14.9 percent revenue growth as EPS misses - AD HOC NEWS
Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00 - AD HOC NEWS
Penumbra, Inc. (PEN) Stock forecasts - Yahoo Finance UK
Revenue per share of Penumbra, Inc. – HAN:0P8 - TradingView
Penumbra stock breaks below 50-day average - AD HOC NEWS
IART vs. PEN: Which Stock Is the Better Value Option? - Zacks Investment Research
Current ratio of Penumbra, Inc. – HAN:0P8 - TradingView
Average basic shares outstanding of Penumbra, Inc. – HAN:0P8 - TradingView
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
IART or PEN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
The Technical Signals Behind (PEN) That Institutions Follow - news.stocktradersdaily.com
Anaconda Biomed raises $56m for catheter portfolio’s advance - Yahoo Finance
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
ETFs Investing in Penumbra, Inc. Stocks - TradingView
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation - AD HOC NEWS
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high - AD HOC NEWS
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Yahoo Finance
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Penumbra, Inc. (PEN) Stock Analysis: Navigating Growth With A 13.88% Potential Upside - DirectorsTalk Interviews
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - directorstalkinterviews.com
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Penumbra Inc Stock (PEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grewal Harpreet | Director |
Apr 02 '26 |
Proposed Sale |
328.22 |
100 |
32,822 |
0 |
| Yuen Maggie | Chief Financial Officer |
Mar 02 '26 |
Sale |
342.30 |
2,432 |
832,474 |
18,353 |
| MAGGIE YUEN | Officer |
Mar 02 '26 |
Proposed Sale |
342.30 |
2,432 |
832,474 |
0 |
| Grewal Harpreet | Director |
Jan 06 '26 |
Proposed Sale |
312.64 |
186 |
58,151 |
0 |
| Grewal Harpreet | Director |
Jan 06 '26 |
Sale |
312.64 |
186 |
58,151 |
8,230 |
| THOMAS WILDER | Director |
Jan 02 '26 |
Proposed Sale |
310.72 |
186 |
57,794 |
0 |
| Wilder Thomas | Director |
Jan 02 '26 |
Sale |
310.72 |
186 |
57,794 |
0 |
| Bose Arani | Director |
Dec 11 '25 |
Sale |
308.82 |
15,000 |
4,632,292 |
258,462 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary |
Dec 05 '25 |
Sale |
300.13 |
300 |
90,039 |
63,836 |
| Grewal Harpreet | Director |
Dec 02 '25 |
Sale |
292.98 |
100 |
29,298 |
8,416 |
0.10%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):